We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 164.80 | 164.80 | 165.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMVEC
RNS Number : 2146M
Vectura Group plc
27 July 2017
Vectura Group plc
Notice of Interim Results
Chippenham, UK, 27 July 2017: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading inhaled airways disease focused business, plans to announce its Interim Results for the six-month period ending 30 June 2017 on Wednesday 6 September 2017.
James Ward-Lilley, Chief Executive Officer, and Andrew Derodra, Chief Financial Officer, will host a briefing for analysts at 9.30am on the morning of the results at the offices of Numis Securities Ltd., 10 Paternoster Square, London, EC4M 7LT.
A live webcast of the meeting, with the presentation slides, will be available on Vectura's website: http://www.vectura.com/investors/presentations-webcasts/.
- ENDS -
For more information, please contact:
Vectura Group plc +44 (0)1249 667700 Andrew Derodra - Chief Financial Officer Fleur Wood - Director Communications Elizabeth Knowles - Director Investor Relations and Analysis Consilium Strategic Communications +44 (0)20 3709 5700 Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.
Vectura has eight inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOROKADKOBKDQOB
(END) Dow Jones Newswires
July 27, 2017 02:03 ET (06:03 GMT)
1 Year Vectura Chart |
1 Month Vectura Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
